SG11201407667UA - MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD - Google Patents

MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

Info

Publication number
SG11201407667UA
SG11201407667UA SG11201407667UA SG11201407667UA SG11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA
Authority
SG
Singapore
Prior art keywords
plgf
sflt
endoglin
preeclampsia
rule
Prior art date
Application number
SG11201407667UA
Other languages
English (en)
Inventor
Martin Hund
Maria Schoedl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407667U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP12183508.6A external-priority patent/EP2706359A1/fr
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201407667UA publication Critical patent/SG11201407667UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201407667UA 2012-06-27 2013-06-24 MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD SG11201407667UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173886 2012-06-27
EP12183508.6A EP2706359A1 (fr) 2012-09-07 2012-09-07 Supports et procédés pour appliquer le taux sFlt-1 ou endogline/PlGF pour éliminer l'apparition de la toxémie prééclamptique dans une certaine période
PCT/EP2013/063115 WO2014001244A1 (fr) 2012-06-27 2013-06-24 Moyens et méthodes d'utilisation du rapport sflt-1/plgf ou endogline/plgf pour écarter le risque d'apparition d'une pré-éclampsie pendant un certain laps de temps

Publications (1)

Publication Number Publication Date
SG11201407667UA true SG11201407667UA (en) 2015-02-27

Family

ID=48741083

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407667UA SG11201407667UA (en) 2012-06-27 2013-06-24 MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

Country Status (11)

Country Link
EP (1) EP2867670B1 (fr)
JP (1) JP5937756B2 (fr)
KR (2) KR20150023063A (fr)
CN (1) CN104412107B (fr)
BR (1) BR112014029233A8 (fr)
CA (1) CA2871878C (fr)
ES (1) ES2681238T3 (fr)
HK (1) HK1208264A1 (fr)
MX (1) MX356775B (fr)
SG (1) SG11201407667UA (fr)
WO (1) WO2014001244A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (fr) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Profil d'expression génétique utilisé comme marqueur de la réceptivité endométriale
US20160025738A1 (en) 2013-03-04 2016-01-28 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
JP6568533B2 (ja) * 2014-01-24 2019-08-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 産後ｈｅｌｌｐ症候群、産後子癇または産後妊娠高血圧腎症の予測
CA2943284A1 (fr) * 2014-03-21 2015-11-05 Igenomix S.L. Detection precoce de pre-eclampsie
SI3158057T1 (sl) 2014-06-17 2019-10-30 Igenomix S L Zdravljenje z matičnimi celicami v patologijah endometrija
WO2017148854A1 (fr) 2016-02-29 2017-09-08 Roche Diagnostics Gmbh Utilisation d'igfbp-7 comme marqueur de pré-éclampsie
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
EP3682250A4 (fr) 2017-09-13 2021-03-03 Progenity, Inc. Biomarqueurs de pré-éclampsie ainsi que systèmes et procédés associés
WO2020016441A1 (fr) * 2018-07-20 2020-01-23 Roche Diagnostics Gmbh Prédiction de prééclampsie fondée sur igfbp -7
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN114200137B (zh) * 2020-09-16 2023-09-01 四川大学 一种以商品化磁珠为内标的比率免疫分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
ES2440651T3 (es) 2002-07-19 2014-01-29 Beth Israel Deaconess Medical Center Método para diagnosticar preeclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
ATE488251T1 (de) * 2004-09-24 2010-12-15 Beth Israel Hospital Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
ATE519109T1 (de) 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
EP2235529B1 (fr) 2008-01-07 2016-12-14 Ortho-Clinical Diagnostics, Inc. Détermination d'un complexe sflt-1 : facteur angiogénique
CN104777307B (zh) 2008-10-31 2019-10-18 耶鲁大学 先兆子痫检测和治疗的方法和组合物
WO2010059952A1 (fr) * 2008-11-20 2010-05-27 Perkinelmer Health Sciences, Inc. Procédé pour déterminer le risque d’éclampsie utilisant les marqueurs pigf-2 et pigf-3
AU2011240039B2 (en) * 2010-04-13 2017-01-19 Mycartis Nv Biomarkers for hypertensive disorders of pregnancy
EP2490027A1 (fr) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Moyens et procédés pour le diagnostic de complications de la grossesse basés sur GDF-15 et PlGF/sFlt1

Also Published As

Publication number Publication date
CA2871878C (fr) 2021-08-10
EP2867670A1 (fr) 2015-05-06
HK1208264A1 (en) 2016-02-26
KR20150023063A (ko) 2015-03-04
KR20160116060A (ko) 2016-10-06
MX356775B (es) 2018-06-13
BR112014029233A8 (pt) 2019-01-29
BR112014029233A2 (pt) 2017-06-27
JP5937756B2 (ja) 2016-06-22
CN104412107B (zh) 2018-06-08
US20150338415A1 (en) 2015-11-26
AU2013283540A1 (en) 2014-11-13
CA2871878A1 (fr) 2014-01-03
MX2014014463A (es) 2015-02-12
JP2015525870A (ja) 2015-09-07
AU2013283540A8 (en) 2014-11-20
KR101996123B1 (ko) 2019-07-03
WO2014001244A1 (fr) 2014-01-03
ES2681238T3 (es) 2018-09-12
CN104412107A (zh) 2015-03-11
EP2867670B1 (fr) 2018-05-30

Similar Documents

Publication Publication Date Title
HK1208264A1 (en) Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf
HK1220279A1 (zh) 預測對精神疾病治療的應答的方法和系統
HK1203855A1 (en) Threads of cross-linked hyaluronic acid and methods of use thereof
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
EP2991588A4 (fr) Valves prothétiques tissulaires et procédé d'ancrage de celles-ci à des structures cardiovasculaires
EP2850745A4 (fr) Agrégation de ballons pour fournir une largeur de bande demandée à l'avance
HK1214154A1 (zh) 局部類固醇組合物和方法
GB2508574B (en) Improvements in and relating to the control of ions
HK1212251A1 (en) Topical compositions and methods of use
EP2888590A4 (fr) Anticorps dirigés contre l'olanzapine et leur utilisation
HK1220520A1 (zh) 預測對疼痛治療的應答的方法和系統
EP2906942A4 (fr) Système et procédé d'analyse fondée sur des processeurs
EP2820881A4 (fr) Procédé et système pour la cessation anticipée des émissions en réponse à un accusé de réception de décodage anticipé
EP2824182A4 (fr) Procédé pour la stimulation de lymphocytes t et son utilisation
EP2991627A4 (fr) Composition de succédané de sang et procédé d'utilisation
EP2828649A4 (fr) Systèmes et procédés pour déterminer et contrôler les changements au niveau de l'état de rails
EP2821504A4 (fr) Procédé permettant de désigner une maladie en relation avec la quantité de tdp-43 présent dans les cellules
HK1224175A1 (zh) 用於減少痂形成並促進癒合的組合物
EP2922413A4 (fr) Compositions de sel à faible teneur en sodium et procédés de fabrication et d'utilisation
BR112016014485A2 (pt) método de alcançar uma mudança de cor em uma composição de cosmético aplicada a um tegumento humano
HK1206610A1 (en) Fully human antibodies that bind to vegfr2 vegfr2
EP2820561A4 (fr) Procédé et système permettant d'utiliser la neuroscience pour prédire une préférence de consommateur
GB2509033B (en) Composition for coloring skin and method for coloring skin
GB2512996B (en) System and method of arbitrating access to interconnect
EP2844219A4 (fr) Composition de sensibilisation et méthode d'utilisation